BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DegludecPlus: Phase IIIa data

The open-label, Asian Phase IIIa NN5401-3597 trial in 424 Type II diabetics showed that once-daily subcutaneous DegludecPlus met the primary endpoint of non-inferiority to NovoMix 30 biphasic insulin aspart in reducing HbA1c from baseline to week...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >